Cytokinetics, Inc.
626 articles about Cytokinetics, Inc.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to EnrollmentCohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy
3/2/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM.
-
Cytokinetics Reports Fourth Quarter 2021 Financial Results
2/24/2022
Cytokinetics, Incorporated reported financial results for the fourth quarter and full year 2021.
-
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
2/23/2022
Cytokinetics, Incorporated today announced that SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment.
-
Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and Awareness of Heart Disease
2/16/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three-year collaboration to accelerate education and awareness of heart disease.
-
Cytokinetics Announces Topline Results From METEORIC-HF
2/15/2022
Cytokinetics, Incorporated today announced topline results from METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv MecarbilRelated to Increased Contractility in Heart Failure), a Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure
-
Cytokinetics to Announce Fourth Quarter Results on February 24, 2022
2/10/2022
Cytokinetics, Incorporated announced that it is scheduled to report fourth quarter results on February 24, 2022 at 4:00 PM Eastern Time.
-
Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction
2/4/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted and filed the company’s New Drug Application (NDA) for omecamtiv mecarbil.
-
Cytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM
2/1/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from Cohort 3 of REDWOOD-HCM.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2022
2/1/2022
Cytokinetics, Incorporated announced that on January 31, 2022 it granted stock options to purchase an aggregate of 200,700 shares of common stock to 15 new employees, whose employment commenced in January 2022, as a material inducement to their employment.
-
Cytokinetics Announces Recipients of Fourth Annual Communications Fellowship Grants
1/24/2022
Cytokinetics, Incorporated announced the recipients of its fourth annual Communications Fellowship Grant program, intended to support increased capacity in communications, awareness building and community engagement for nonprofit organizations serving the patient community.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 10, 2022
1/10/2022
Cytokinetics, Incorporated announced that on December 31, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to 9 new employees, whose employment commenced in December 2021, as a material inducement to their employment.
-
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
1/7/2022
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten.
-
Cytokinetics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 pm ET.
-
Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
12/20/2021
Cytokinetics, Incorporated (Nasdaq: CYTK) and Ji Xing Pharmaceuticals Limited today announced an expansion of their collaboration by entering into an exclusive license and collaboration agreement to develop and commercialize omecamtiv mecarbil for the proposed treatment of heart failure with reduced ejection fraction (HFrEF) in Greater China.
-
Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to Fast Disease Progression Phenotype at Baseline
12/10/2021
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 32nd International Symposium on ALS/MND including an analysis of baseline characteristics from the initial patients enrolled in COURAGE-ALS.
-
Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for AficamtenFDA Granted Designation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Based on Results of REDWOOD-HCM
12/9/2021
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2021
12/1/2021
Cytokinetics, Incorporated announced that on November 30, 2021 it granted stock options to purchase an aggregate of 143,500 shares of common stock to 9 new employees, whose employment commenced in November 2021, as a material inducement to their employment.
-
Cytokinetics Announces Four Presentations at the 32nd International Symposium on ALS/MND
11/30/2021
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three poster presentations at the 32nd International Symposium on ALS/MND taking place online from December 7 – December 10, 2021.
-
Cytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021
11/15/2021
Cytokinetics, Incorporated announced that additional results from GALACTIC-HF, the Phase 3 clinical trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction, were presented by Dr. John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF, at the American Heart Association Scientific Sessions 2021.